CompletedPhase 2

Eculizumab for Prevention and Treatment of Kidney Graft Reperfusion Injury

Russia57 participantsStarted 2012-09-01

Plain-language summary

Study of eculizumab ability to correct the reperfusion injury of the kidney allograft.

Age range12 Months – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✓. age 1-80
✓. weight - \>6 kg
✓. male or female
✓. recipient of first kidney graft either from standard criteria deceased or live donor
✓. end stage renal disease or congenital nephrotic syndrome -

✕. Blood group (ABO) incompatible transplantation
✕. presence of donor-specific anti-human leukocyte antigen (HLA) antibodies
✕. multiorgan transplantation
✕. previous transplant
✕. patients infected with HIV, hepatitis C virus (HCV) or hepatitis B virus (HBV)
✕. patients with haemolytic-uraemic syndrome (HUS) -

speed of the graft warming

Timeframe: at the time of engraftment

NCT IDNCT01756508

SponsorRussian Academy of Medical Sciences

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2017-04-15